DADC
ADPT icon

D.A. Davidson & Co’s Adaptive Biotechnologies ADPT Stock Holding History

D.A. Davidson & Co’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$460K Sell
21,450
-4,300
-17% -$65.9K ﹤0.01% 1238
2026
Q1 		$357K Sell
25,750
-60,300
-70% -$961K ﹤0.01% 1293
2025
Q4 		$1.4M Sell
86,050
-150
-0.2% -$2.45K 0.01% 784
2025
Q3 		$1.29M Sell
86,200
-4,400
-5% -$53.6K 0.01% 784
2025
Q2 		$1.06M Sell
90,600
-1,250
-1% -$11.4K 0.01% 799
2025
Q1 		$682K Buy
91,850
+3,400
+4% +$26.1K 0.01% 905
2024
Q4 		$530K Buy
88,450
+6,725
+8% +$37.1K ﹤0.01% 989
2024
Q3 		$418K Sell
81,725
-4,500
-5% -$19.6K ﹤0.01% 1082
2024
Q2 		$312K Buy
86,225
+28,100
+48% +$89.2K ﹤0.01% 1148
2024
Q1 		$187K Buy
58,125
+11,150
+24% +$43.1K ﹤0.01% 1298
2023
Q4 		$230K Sell
46,975
-6,900
-13% -$31.5K ﹤0.01% 1200
2023
Q3 		$294K Sell
53,875
-29,400
-35% -$194K ﹤0.01% 1093
2023
Q2 		$559K Buy
83,275
+29,550
+55% +$220K 0.01% 891
2023
Q1 		$474K Buy
53,725
+15,325
+40% +$135K 0.01% 909
2022
Q4 		$293K Sell
38,400
-3,150
-8% -$24.5K ﹤0.01% 1052
2022
Q3 		$296K Buy
41,550
+1,385
+3% +$13K ﹤0.01% 1008
2022
Q2 		$325K Buy
40,165
+15,370
+62% +$135K ﹤0.01% 975
2022
Q1 		$344K Buy
24,795
+6,850
+38% +$108K ﹤0.01% 1019
2021
Q4 		$504K Buy
17,945
+1,160
+7% +$35.6K 0.01% 874
2021
Q3 		$571K Buy
16,785
+875
+5% +$31.6K 0.01% 794
2021
Q2 		$650K Buy
15,910
+525
+3% +$20.4K 0.01% 756
2021
Q1 		$619K Buy
15,385
+4,750
+45% +$257K 0.01% 735
2020
Q4 		$629K Sell
10,635
-100
-0.9% -$5.16K 0.01% 629
2020
Q3 		$522K Sell
10,735
-280
-3% -$11.8K 0.01% 601
2020
Q2 		$533K Sell
11,015
-5,375
-33% -$196K 0.01% 576
2020
Q1 		$455K Buy
16,390
+3,120
+24% +$87K 0.01% 615
2019
Q4 		$397K Buy
+13,270
New +$381K 0.01% 737

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

D.A. Davidson & Co's ADPT Position: Q2 2026 in Review

D.A. Davidson & Co reduced its Adaptive Biotechnologies (ADPT) stake by 17% in Q2 2026, selling an estimated $65.9K and leaving 21,450 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #1238.

D.A. Davidson & Co first reported a position in ADPT in Q4 2019 and has held it in 27 quarters since. The position peaked at $1.4M in Q4 2025. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • D.A. Davidson & Co held 21,450 shares of Adaptive Biotechnologies worth $460K as of Q2 2026.
  • D.A. Davidson & Co sold 4,300 Adaptive Biotechnologies shares in Q2 2026, an estimated $65.9K.
  • Adaptive Biotechnologies made up ﹤0.01% of D.A. Davidson & Co's portfolio in Q2 2026, its #1238 holding.
  • D.A. Davidson & Co first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 27 quarters since.
  • D.A. Davidson & Co's Adaptive Biotechnologies position peaked at $1.4M in Q4 2025.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.